Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conatumumab with Chemoradiation for Locally Advanced Pancreatic Cancer
NCT01017822Phase 2Withdrawn
- Sponsor
- NRG Oncology
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 2 trial of conatumumab in pancreatic adenocarcinoma (PDAC), sponsored by NRG Oncology. Status: withdrawn.
02
Drugs
conatumumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01017822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01017822.